The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Management of cognitive deficits in Major Depressive Disorder (MDD) remains an important unmet need. This meta-analysis evaluated the effects of vortioxetine on cognition in patients with MDD. METHODS: Random effects meta-analysis was applied to three randomized, double-blind, placebo-controlled 8-week trials of vortioxetine (5-20mg/day) in MDD, and separately to two duloxetine-referenced trials. The primary outcome measure was change in Digit Symbol Substitution Test (DSST) score. Standardized effect sizes (SES) versus placebo (Cohen's d ) were used as input. Path analysis was employed to determine the extent to which changes in DSST were mediated independently of a change in Montgomery-Åsberg Depression Rating Scale (MADRS) score. Meta-analysis was applied to MADRS-adjusted and -unadjusted SES values. Changes on additional cognitive tests were evaluated (source studies only). RESULTS: Before adjustment for MADRS, vortioxetine separated from placebo on DSST score (SES 0.25-0.48; nominal p < 0.05) in all individual trials, and statistically improved DSST performance versus placebo in meta-analyses of the three trials (SES = 0.35; p < 0.0001) and two duloxetine-referenced trials (SES = 0.26; p = 0.001). After adjustment for MADRS, vortioxetine maintained DSST improvement in one individual trial ( p = 0.001) and separation from placebo was maintained in meta-analyses of all three trials (SES = 0.24; p < 0.0001) and both duloxetine-referenced trials (SES 0.19; p = 0.01). Change in DSST with duloxetine failed to separate from placebo in individual trials and both meta-analyses. Change in DSST statistically favored vortioxetine versus duloxetine after MADRS adjustment (SES = 0.16; p = 0.04). CONCLUSIONS: Vortioxetine, but not duloxetine, significantly improved cognition, independent of depressive symptoms. Vortioxetine represents an important treatment for MDD-related cognitive dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In clinical studies of patients with MDD, vortioxetine has shown significant and clinically relevant effects not only on depressive symptoms, but also on the physical and cognitive symptoms of depression (Christensen et al., 2018a;Kelliny et al., 2015;McIntyre et al., 2016).”
From Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment (2021) · cites this paper as McIntyre et al., 2016
Experimental — accuracy not yet measuredIn the citing paper
“Hitherto, only 2 antidepressants (ie, duloxetine and vortioxetine) have demonstrated direct, independent, and clinically relevant effects on cognitive dysfunction in MDD. 8”
From Cognitive Impairment in Major Depressive Disorder (2019) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“The I2 value in the meta-analysis of unadjusted data for the three trials was 42% (data not shown), indicating a low likelihood that study heterogeneity had a relevant impact on effect estimates (Higgins et al., 2003).”
MethodA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 2×
“These were similarly designed, 8-week, randomized, double-blind, placebo-controlled trials in patients who met the Diagnostic and Statistical Manual of Mental Disorders criteria for recurrent MDD (Fourth Edition, Text Revision; DSM-IV-TR; American Psychiatric Association, 2000b) and had a MADRS (Montgomery and Åsberg,…”
BackgroundMethodCognitive impairment in depression: a systematic review and meta-analysis
Rock, P. L., Roiser, J. P., Riedel, W. J., & Blackwell, A. D. (2014) · Psychological Medicine · doi:10.1017/s0033291713002535 · Cited by 2,161 · cited 1×
“7 (Lee et al., 2012; Snyder, 2013; Rock et al., 2014), a magnitude of cognitive decline that is anticipated to have a profound impact on occupational and school performance.”
BackgroundSnyder, H. R. (2013) · Psychological Bulletin · doi:10.1037/a0028727 · Cited by 1,667 · cited 2×
“…tests) observed in patients with MDD relative to healthy controls, for which metaanalyses indicate that the typical SES are 0.2–0.7 (Lee et al., 2012; Snyder, 2013; Rock et al., 2014), a magnitude of cognitive decline that is anticipated to have a profound impact on occupational and school…”
BackgroundInfluentialDistributed Disturbances in Brain Structure and Function in Schizophrenia
(2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.1 · Cited by 969
McIntyre, R. S., Cha, D. S., Soczynska, J. K., Woldeyohannes, H. O., Gallaugher, L. A., Kudlow, P., Alsuwaidan, M., & Baskaran, A. (2013) · Depression and Anxiety · doi:10.1002/da.22063 · Cited by 765
Self-citationA meta-analysis of cognitive deficits in first-episode Major Depressive Disorder
Lee, R. S. C., Hermens, D. F., Porter, M. A., & Redoblado-Hodge, M. A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.023 · Cited by 737 · cited 1×
“7 (Lee et al., 2012; Snyder, 2013; Rock et al., 2014), a magnitude of cognitive decline that is anticipated to have a profound impact on occupational and school performance.”
BackgroundPatterson, T. L., Goldman, S., McKibbin, C. L., Hughs, T., & Jeste, D. V. (2001) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006870 · Cited by 737
Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547 · cited 3×
“Other mechanisms hypothesized to contribute to the pro-cognitive effects of vortioxetine in animal models include direct and/or indirect effects via serotonergic, noradrenergic, cholinergic, dopaminergic, and histaminergic systems (Sanchez et al., 2015).”
BackgroundThe course of geriatric depression with "reversible dementia": a controlled study
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.11.1693 · Cited by 505
Cognitive functioning in major depression – a summary
Hammar, Å. (2009) · Frontiers in Human Neuroscience · doi:10.3389/neuro.09.026.2009 · Cited by 491 · cited 2×
“…processing and verbal fluency reduce the capacity for normal daily functioning (National Academies of Sciences, Engineering, and Medicine, 2015), while the impact on family and social interactions can strain relationships and lead to household tension (Hammar and Ardal, 2009; Lam et al., 2014).”
BackgroundLeucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451 · cited 1×
“Moreover, the observed SES with vortioxetine are consistent with, and similar to, those reported for many drugs used in general medical and psychiatric practice (e.g. paroxetine, fluoxetine, and lithium; Leucht et al., 2012), and in disorders of cognition (e.”
ResultKatona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445 · cited 3×
“Since such dysfunction is more pronounced in elderly patients with MDD than in younger depressed adults, this hypothesis was initially examined in a controlled, duloxetine-referenced trial in patients aged ≥65 years (Katona et al., 2012).”
BackgroundResultSelf-citationLam, R. W., Kennedy, S. H., McIntyre, R. S., & Khullar, A. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405901206 · Cited by 438 · cited 1×
“In particular, deficiencies in memory and the cognitive substrates of information processing and verbal fluency reduce the capacity for normal daily functioning (National Academies of Sciences, Engineering, and Medicine, 2015), while the impact on family and social interactions can strain relationships and lead to hou…”
BackgroundSelf-citationMcIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433 · cited 8×
“The majority of patients were female, with a mean age of approximately 45 years in two trials (McIntyre et al., 2014; Mahableshwarkar et al., 2015) and 70 years in the third (Katona et al.”
BackgroundMethodResultInfluentialSelf-citationRaskin, J., Wiltse, C. G., Siegal, A., Sheikh, J., Xu, J., Dinkel, J. J., Rotz, B. T., & Mohs, R. C. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.164.6.900 · Cited by 336
Raskin, J., Wiltse, C. G., Siegal, A., Sheikh, J., Xu, J., Dinkel, J. J., Rotz, B. T., & Mohs, R. C. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.900 · Cited by 329 · cited 1×
“These tests were chosen based on evidence suggesting that duloxetine was superior to placebo on the RAVLT, but not on tests that have a greater impact on executive function (DSST, the Two-Digit Cancellation Test, and the Letter-Number Sequencing Test), including a symbol coding test equivalent to the DSST (Raskin et a…”
MethodCognitive remediation therapy in schizophrenia: Randomised controlled trial
Wykes, T., Reeder, C., Landau, S., Everitt, B., Knapp, M., Patel, A., & Romeo, R. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.026575 · Cited by 328 · cited 1×
“They are also in accordance with effect sizes for recognized non-pharmacological cognitive interventions such as cognitive remediation therapy in schizophrenia (SES = 0.34; Wykes et al., 2007).”
ResultInfluentialRosenblat, J. D., Kakar, R., & McIntyre, R. S. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv082 · Cited by 315 · cited 2×
“Evidence, although limited, suggests that mechanistically dissimilar antidepressants exert significantly positive effects on delayed recall and the cognitive substrates of psychomotor speed (Rosenblat et al., 2015).”
BackgroundSelf-citationMahableshwarkar, A. R., Zajecka, J., Jacobson, W., Chen, Y., & Keefe, R. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.52 · Cited by 307 · cited 11×
“executive function, processing speed, and attention) and can detect changes in cognitive function if treatment is effective, including in subsets of patients who are non-responders or non-remitters (McIntyre et al., 2013; Mahableshwarkar et al., 2015).”
BackgroundMethodResultInfluentialSelf-citationMemantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Matsunaga, S., Kishi, T., & Iwata, N. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123289 · Cited by 284 · cited 1×
“, 2012), and in disorders of cognition (e.g. memantine in Alzheimer’s Disease; SES = 0.27; Matsunaga et al., 2015).”
BackgroundInfluentialDitlevsen, S., Christensen, U., Lynch, J., Damsgaard, M. T., & Keiding, N. (2005) · Epidemiology · doi:10.1097/01.ede.0000147107.76079.07 · Cited by 246
Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review
Bortolato, B., Carvalho, A., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130203823 · Cited by 181
Self-citationKorczyn, A. D., & Halperin, I. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.02.346 · Cited by 179
McIntyre, R. S., Soczynska, J. K., Woldeyohannes, H. O., Alsuwaidan, M. T., Cha, D. S., Carvalho, A. F., Jerrell, J. M., Dale, R. M., Gallaugher, L. A., Muzina, D. J., et al. (2014) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2014.08.051 · Cited by 171 · cited 1×
“Results: Before adjustment for MADRS, vortioxetine separated from placebo on DSST score (SES 0.25–0.48; nominal p < 0.05) in all individual trials, and statistically improved DSST performance versus placebo in meta-analyses of the three trials (SES = 0.35; p < 0.0001) and two duloxetine-referenced…”
InfluentialSelf-citationSedative effects of antihistamines
Roth, T., Roehrs, T., Koshorek, G., Sicklesteel, J., & Zorick, F. (1987) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(87)80197-5 · Cited by 151 · cited 2×
“Studies of DSST performance relative to placebo have shown effect sizes (Cohen’s d) of 0.25–0.5 for diphenhydramine (Roth et al., 1987) and lorazepam (Pompeia et al., 2008), and 0.68 in people whose blood alcohol concentration is 0.09% (Mattila and Mattila-Evenden, 1997; national guidelines…”
BackgroundInfluentialPatten, S. B., Kennedy, S. H., Lam, R. W., O'Donovan, C., Filteau, M. J., Parikh, S. V., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.044 · Cited by 148
McIntyre, R. S., Xiao, H. X., Syeda, K., Vinberg, M., Carvalho, A. F., Mansur, R. B., Maruschak, N., & Cha, D. S. (2015) · CNS Drugs · doi:10.1007/s40263-015-0263-x · Cited by 145 · cited 1×
“Key words: cognitive function, duloxetine, major depressive disorder, meta-analysis, vortioxetine”
BackgroundSelf-citationLong-term outcome of depressive pseudodementia in the elderly
Fonseca, J. A. S., Lee, L., & Walker, Z. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.11.004 · Cited by 111
Wallace, A., Pehrson, A. L., Sánchez, C., & Morilak, D. A. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000571 · Cited by 97 · cited 1×
“The novel multimodal antidepressant vortioxetine has shown evidence of cognitive benefit in animal models, where it improved measures of memory (e.g. reversal learning; Wallace et al., 2014; Sanchez et al., 2015), as well as in patients with MDD (Katona et al.”
BackgroundTiming as a window on cognition in schizophrenia
Ward, R. D., Kellendonk, C., Kandel, E. R., & Balsam, P. D. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.014 · Cited by 97 · cited 1×
“Notably, vortioxetine was statistically significantly superior to placebo in decreasing the difficulty of time management, which is closely correlated with cognitive function (Ward et al., 2012; Mioni et al., 2013).”
BackgroundPehrson, A. L., Leiser, S. C., Gulinello, M., Dale, E., Li, Y., Waller, J. A., & Sanchez, C. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.044 · Cited by 91 · cited 2×
“The pharmacodynamic mechanisms proposed to mediate the effects of vortioxetine on cognitive dysfunction in patients with MDD are believed to include increased glutamate neurotransmission (via inhibition of gamma-aminobutyric acid [GABA] interneurons expressing 5-HT3 heteroreceptors) and neuroplasticity in brain region…”
BackgroundXiang, X., & An, R. (2015) · Psychiatric Services · doi:10.1176/appi.ps.201400511 · Cited by 49 · cited 1×
“Available evidence also indicates that health service utilization and costs related to healthcare expenditure are greater in individuals with MDD and cognitive dysfunction when compared to those who have MDD but no cognitive deficits (Xiang and An, 2015).”
BackgroundFlorea, I., Danchenko, N., Brignone, M., Loft, H., Rive, B., & Abetz-Webb, L. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.008 · Cited by 35 · cited 2×
“In two of the source studies (Katona et al., 2012; Mahableshwarkar et al., 2015), duloxetine 60 mg/day was used as an active reference for assay sensitivity.”
MethodInfluentialSelf-citationRiga, M. S., Celada, P., Sánchez, C., & Artigas, F. (2013) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(13)70621-7 · Cited by 25 · cited 2×
“The pharmacodynamic mechanisms proposed to mediate the effects of vortioxetine on cognitive dysfunction in patients with MDD are believed to include increased glutamate neurotransmission (via inhibition of gamma-aminobutyric acid [GABA] interneurons expressing 5-HT3 heteroreceptors) and neuroplasticity in brain region…”
BackgroundPatient Safety Considerations in the Rehabilitation of the Individual with Cognitive Impairment
Tyson, B. T., Pham, M. T., Brown, N. T., & Mayer, T. R. (2012) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2012.02.007 · Cited by 23 · cited 1×
“In the sphere of public health, compromised executive function and attention, slowed information processing, and poor judgment have important safety implications, increasing the risk of motor vehicle accidents, falls, and medication errors (Tyson et al., 2012).”
BackgroundTime discrimination in traumatic brain injury patients
Mioni, G., Stablum, F., & Cantagallo, A. (2012) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2012.755151 · Cited by 17
Mattila, M. J., & Mattila‐Evenden, M. (1997) · Journal of Psychopharmacology · doi:10.1177/026988119701100405 · Cited by 16 · cited 1×
“…0.25–0.5 for diphenhydramine (Roth et al., 1987) and lorazepam (Pompeia et al., 2008), and 0.68 in people whose blood alcohol concentration is 0.09% (Mattila and Mattila-Evenden, 1997; national guidelines usually stipulate an upper threshold of either 0.05 or 0.08%;…”
BackgroundInfluentialEffects of lorazepam on visual perceptual abilities
Pompéia, S., Pradella-Hallinan, M. L. D. C., Manzano, G. M., & Bueno, O. F. A. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.927 · Cited by 15 · cited 2×
“Studies of DSST performance relative to placebo have shown effect sizes (Cohen’s d) of 0.25–0.5 for diphenhydramine (Roth et al., 1987) and lorazepam (Pompeia et al., 2008), and 0.68 in people whose blood alcohol concentration is 0.09% (Mattila and Mattila-Evenden, 1997; national guidelines…”
BackgroundInfluentialHaddjeri, N., Etiévant, A., Pehrson, A. L., Sánchez, C., & Betry, C. (2012) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(12)70462-5 · Cited by 12 · cited 2×
“The pharmacodynamic mechanisms proposed to mediate the effects of vortioxetine on cognitive dysfunction in patients with MDD are believed to include increased glutamate neurotransmission (via inhibition of gamma-aminobutyric acid [GABA] interneurons expressing 5-HT3 heteroreceptors) and neuroplasticity in brain region…”
BackgroundSciences, E. N. A. O. (2015) · National Academies Press eBooks · doi:10.17226/21745 · Cited by 5
Research works printed but not linked: 1
- 10.1097/01.ede.0000147107.76079.07 · DOI · Paper page
Cited by
Malhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614
“There are data suggesting that vortioxetine may be helpful for some aspects of cognitive function in major depression, but the effects are relatively narrow and are related to the treatment of acute depression (McIntyre et al., 2016).”
BackgroundCognitive Impairment in Major Depressive Disorder
Pan, Z., Park, C., Brietzke, E., Zuckerman, H., Rong, C., Mansur, R. B., Fus, D., Subramaniapillai, M., Lee, Y., & McIntyre, R. S. (2019) · CNS Spectrums · doi:10.1017/s1092852918001207 · Cited by 320
“Duloxetine did not exhibit a statistically significant improvement when compared to placebo on composite measures of cognitive function in contradistinction to vortioxetine.(67) In addition, vortioxetine appears to improve a broader range of cognitive functions (ie, executive function, learning, memory, processing spe…”
MethodResultSelf-citationPrévot, T., & Sibille, E. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0727-3 · Cited by 231
Miskowiak, K., Burdick, K., Martinez‐Aran, A., Bonnin, C., Bowie, C., Carvalho, A., Gallagher, P., Lafer, B., López‐Jaramillo, C., Sumiyoshi, T., et al. (2017) · Bipolar Disorders · doi:10.1111/bdi.12534 · Cited by 216
Self-citationMiskowiak, K., Burdick, K., Martinez‐Aran, A., Bonnin, C., Bowie, C., Carvalho, A., Gallagher, P., Lafer, B., López‐Jaramillo, C., Sumiyoshi, T., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12595 · Cited by 213
Self-citation
Metadata
- Authors
- McIntyre, R., Harrison, J., Loft, H., Jacobson, W., & Olsen, C.
- Corresponding author
- McIntyre, RS
- ORCID
- Harrison, J
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-06-15
- Volume
- 19
- Issue
- 10
- Pages
- pyw055
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC5091829
- OpenAlex
- W2436735416
- Cited by
- 185
- References
- 44
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 17 · 2023: 14 · 2022: 25 · 2021: 23 · 2020: 20 · 2019: 27 · 2018: 17 · 2017: 15 · 2016: 5
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- HighWire Press Open Archive (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Takeda Pharmaceuticals U.S.A.
- H. Lundbeck A/S
- University of California, San Diego
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- vortioxetine, major depressive disorder, cognitive function, cognitive impairment, duloxetine, Digit Symbol Substitution Test, neuropsychological outcomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.